This study conducted by Swedish Orphan Biovitrum (Sobi) is a phase 4 multicenter, observational, clinical trial for adults with ITP over the age of 18 years. The goal of the study is to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base in routine medical practice. Both retrospective and prospective data will be collected.
The main part of the study will be prospective collecting data on usage, effectiveness, safety, and on patient- and clinician-reported outcomes using Doptelet. The retrospective part will consist of collecting information on previous treatments, reasons for treatment switches, healthcare resource use and Doptelet treatment prior to enrollment. The retrospective data collection will be based on the information available in the patient's medical records. Participants will be excluded from participating if they have secondary ITP or have taken an ’investigational medicinal product’ within three months of enrolled into the study.
Croatia, Czechia, Germany, Ireland, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Status: Recruiting
